These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35562252)

  • 1. Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma.
    Laukhtina E; Hassler MR; Pradere B; Yanagisawa T; Quhal F; Rajwa P; Sari Motlagh R; König F; Pallauf M; Kawada T; Mostafaei H; D'Andrea D; Enikeev D; Shariat SF
    Eur Urol Focus; 2022 Nov; 8(6):1683-1686. PubMed ID: 35562252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
    Liu H; Chen J; Huang Y; Zhang Y; Ni Y; Xu N; Zhao F; Tang Y; Liu H; Sun G; Shen P; Liu Z; Huang J; Liao B; Zeng H
    Int J Surg; 2024 Jun; 110(6):3923-3936. PubMed ID: 38573063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
    Powles T; Assaf ZJ; Degaonkar V; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Sethi H; Aleshin A; Shi Y; Davarpanah N; Carter C; Bellmunt J; Mariathasan S
    Eur Urol; 2024 Feb; 85(2):114-122. PubMed ID: 37500339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
    Crupi E; de Padua TC; Marandino L; Raggi D; Dyrskjøt L; Spiess PE; Sonpavde GP; Kamat AM; Necchi A
    Eur Urol Oncol; 2024 Feb; 7(1):44-52. PubMed ID: 37330413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
    Tolmeijer SH; van Wilpe S; Geerlings MJ; von Rhein D; Smilde TJ; Kloots ISH; Westdorp H; Coskuntürk M; Oving IM; van Ipenburg JA; van der Heijden AG; Hofste T; Weiss MM; Schalken JA; Gerritsen WR; Ligtenberg MJL; Mehra N
    Eur Urol Oncol; 2024 Apr; 7(2):282-291. PubMed ID: 37673768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
    Powles T; Assaf ZJ; Davarpanah N; Banchereau R; Szabados BE; Yuen KC; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Zimmermann BG; Sethi H; Aleshin A; Perdicchio M; Zhang J; Shames DS; Degaonkar V; Shen X; Carter C; Bais C; Bellmunt J; Mariathasan S
    Nature; 2021 Jul; 595(7867):432-437. PubMed ID: 34135506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
    Lindskrog SV; Birkenkamp-Demtröder K; Nordentoft I; Laliotis G; Lamy P; Christensen E; Renner D; Andreasen TG; Lange N; Sharma S; ElNaggar AC; Liu MC; Sethi H; Aleshin A; Agerbæk M; Jensen JB; Dyrskjøt L
    Clin Cancer Res; 2023 Dec; 29(23):4797-4807. PubMed ID: 37782315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
    Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
    Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
    Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.
    Zang J; Zhang R; Jin D; Xie F; Shahatiaili A; Wu G; Zhang Y; Zhao Z; Du P; Jia S; Chen H; Zhuang G
    J Pathol; 2023 Oct; 261(2):198-209. PubMed ID: 37584165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.
    Chalfin HJ; Glavaris SA; Gorin MA; Kates MR; Fong MH; Dong L; Matoso A; Bivalacqua TJ; Johnson MH; Pienta KJ; Hahn NM; McConkey DJ
    Eur Urol Oncol; 2021 Apr; 4(2):310-314. PubMed ID: 31563523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.
    Green EA; Li R; Albiges L; Choueiri TK; Freedman M; Pal S; Dyrskjøt L; Kamat AM
    Eur Urol Oncol; 2021 Dec; 4(6):893-903. PubMed ID: 33975782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011.
    Grunewald CM; Niegisch G; Albers P
    Eur Urol Focus; 2022 May; 8(3):646-647. PubMed ID: 35450799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder.
    Laukhtina E; Pradere B; Lemberger U; Karakiewicz PI; Fajkovic H; Shariat SF
    Curr Opin Urol; 2022 Sep; 32(5):561-566. PubMed ID: 35849719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.
    Blumendeller C; Boehme J; Frick M; Schulze M; Rinckleb A; Kyzirakos C; Kayser S; Kopp M; Kelkenberg S; Pieper N; Bartsch O; Hadaschick D; Battke F; Stenzl A; Biskup S
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
    Rose KM; Huelster HL; Meeks JJ; Faltas BM; Sonpavde GP; Lerner SP; Ross JS; Spiess PE; Grass GD; Jain RK; Kamat AM; Vosoughi A; Wang L; Wang X; Li R
    Nat Rev Urol; 2023 Jul; 20(7):406-419. PubMed ID: 36977797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating DNA in the neoadjuvant setting of early stage colon cancer.
    Bregni G; Pretta A; Senti C; Acedo Reina E; Vandeputte C; Trevisi E; Gkolfakis P; Kehagias P; Deleporte A; Van Laethem JL; Vergauwe P; Van den Eynde M; Deboever G; Janssens J; Demolin G; Holbrechts S; Clausse M; De Grez T; Peeters M; D'Hondt L; Geboes K; Besse-Hammer T; Rothé F; Flamen P; Hendlisz A; Sclafani F
    Acta Oncol; 2022 Oct; 61(10):1223-1229. PubMed ID: 35866544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.